SPRY has 36-month beta value of 0.83. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 54.77M, and currently, short sellers hold a 30.54% ratio of that float. The average trading volume of SPRY on May 22, 2025 was 1.74M shares.
SPRY) stock’s latest price update
ARS Pharmaceuticals Inc (NASDAQ: SPRY) has experienced a decline in its stock price by -0.77 compared to its previous closing price of 14.33. However, the company has seen a gain of 17.52% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-14 that ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma – CBO Richard Lowenthal – Co-Founder, President and CEO Eric Karas – CCO Kathleen Scott – CFO Conference Call Participants Ryan Deschner – Raymond James Josh Schimmer – Cantor Roanna Ruiz – Leerink Partners Lachlan Hanbury-Brown – William Blair Andreas Argyrides – Oppenheimer Louise Chen – Scotiabank Operator Good morning and welcome to ARS Pharmaceuticals’ Conference Call. At this time, all participants are in listen-only mode.
SPRY’s Market Performance
ARS Pharmaceuticals Inc (SPRY) has seen a 17.52% rise in stock performance for the week, with a -5.20% decline in the past month and a 20.71% surge in the past quarter. The volatility ratio for the week is 7.17%, and the volatility levels for the past 30 days are at 5.69% for SPRY. The simple moving average for the last 20 days is 3.38% for SPRY’s stock, with a simple moving average of 8.34% for the last 200 days.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Scotiabank repeating the rating for SPRY by listing it as a “Sector Outperform.” The predicted price for SPRY in the upcoming period, according to Scotiabank is $30 based on the research report published on March 07, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $40. The rating they have provided for SPRY stocks is “Outperform” according to the report published on February 10th, 2025.
SPRY Trading at 6.22% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.18% of loss for the given period.
Volatility was left at 5.69%, however, over the last 30 days, the volatility rate increased by 7.17%, as shares sank -1.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.33% upper at present.
During the last 5 trading sessions, SPRY rose by +17.52%, which changed the moving average for the period of 200-days by +43.64% in comparison to the 20-day moving average, which settled at $13.76. In addition, ARS Pharmaceuticals Inc saw 34.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Scott Kathleen D., who proposed sale 50,000 shares at the price of $14.10 back on May 20 ’25. After this action, Scott Kathleen D. now owns shares of ARS Pharmaceuticals Inc, valued at $705,000 using the latest closing price.
Fitzpatrick Alexander A, the Officer of ARS Pharmaceuticals Inc, proposed sale 102,969 shares at $14.02 during a trade that took place back on May 20 ’25, which means that Fitzpatrick Alexander A is holding shares at $1,443,894 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.91 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -0.16. The total capital return value is set at -0.09. Equity return is now at value -6.91, with -5.64 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -280.6.
Currently, EBITDA for the company is -3.08 million with net debt to EBITDA at 1.47. When we switch over and look at the enterprise to sales, we see a ratio of 13.97. The receivables turnover for the company is 10.44for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.00.
Conclusion
To put it simply, ARS Pharmaceuticals Inc (SPRY) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
